Funding for this research was provided by:
Received: 29 April 2019
Accepted: 21 October 2019
First Online: 9 December 2019
Change Date: 9 June 2020
Change Type: Correction
Change Details: An amendment to this paper has been published and can be accessed via the original article.
Ethics approval and consent to participate
: The protocol was approved by the independent ethics committees or institutional review boards at all study sites. All participants provided written informed consent before enrolment. The RCT was conducted in accordance with the ethical principles that have their origin in the current Declaration of Helsinki and consistent with International Conference on Harmonisation Good Clinical Practice and Good Epidemiology Practices, along with all applicable local regulatory requirements. All patient data were de-identified and complied with patient confidentiality requirements.
: Not applicable.
: VS is a consultant for AbbVie, Amgen, AstraZeneca, BMS, Celgene, Genentech, GSK, Janssen, Lilly, Novartis, Pfizer, Regeneron, Sanofi, and UCB, and is involved in the advisory boards for AbbVie, Amgen, AstraZeneca, BMS, Celgene, Genentech, GSK, Janssen, Lilly, Novartis, Pfizer, Regeneron, Sanofi, and UCB. JP is a consultant for AbbVie, Amgen, BMS, Celltrion, GSK, Lilly, Merck, Novartis, Pfizer, Roche, Sandoz, Sanofi, and UCB. NT, AF, HSC, AP, AG, and MF are employees of AbbVie and may own AbbVie stock or stock options. DG is an employee of Analysis Group, Inc., which received consulting fees from AbbVie for this study. MS is a consultant for AbbVie, BMS, Eli Lilly, JNJ, and UCB, and is a member of the speaker bureau for AbbVie and BMS.